Revolutionizing T-cells for solid tumor cell therapies, Gary Lee, CSO, Lyell Immunopharma

Revolutionizing T-cells for solid tumor cell therapies, Gary Lee, CSO, Lyell Immunopharma

Synopsis: Gary Lee, Ph.D. is the CSO of Lyell Immunopharma, a T-cell reprogramming company dedicated to developing cell therapies for patients with solid tumors. A chemical engineer by training, Gary has been working in the gene therapy field for 20+ years. He discusses how he’s observed the cell therapy space evolve over the last couple of decades. He talks about the work his team is doing to develop effective cell-based therapies for solid tumor cancers and where they are from a development and team-building perspective. He also provides his perspective on opportunities he sees for future technology across the cell therapy landscape. Biography: Gary Lee, Ph.D., has served as our Chief Scientific Officer since January 2022. Dr. Lee is a veteran biotech executive with over a decade of experience leading cell and gene therapy programs for human applications. From October 2018 to January 2022, Dr. Lee was the Chief Scientific Officer at Senti Bio. From August 2005 to October 2018, Dr. Lee held positions of increasing scientific and leadership responsibility at Sangamo Therapeutics, including last as the Vice President of Cell Therapy. Dr. Lee earned his Ph.D. in Chemical Engineering from the University of California, Berkeley, and his B.S. in Chemical Engineering from the California Institute of Technology.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(265)

Robert Plenge, EVP & Chief Research Officer, BMS: Reinventing Drug Discovery

Robert Plenge, EVP & Chief Research Officer, BMS: Reinventing Drug Discovery

Synopsis: The drug discovery industry faces a persistent challenge: 9 out of 10 drugs entering the clinic fail, underscoring the need for a better path from biological insight to transformative medi...

24 Sep 45min

Nello Mainolfi, Founder, President & CEO, Kymera: Pioneering Targeted Protein Degradation

Nello Mainolfi, Founder, President & CEO, Kymera: Pioneering Targeted Protein Degradation

Synopsis: What does it take to turn a once-fringe scientific idea into a new approach to drug discovery—and build a biotech company around it for the long haul? In this episode of Biotech 2050, hos...

16 Sep 38min

Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery

Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery

Synopsis: The guest on today's podcast is a representative of Braidwell LP, a registered investment adviser. Braidwell invests on behalf of its clients and either holds, or may in the future hold, p...

3 Aug 47min

Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership

Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership

Synopsis: In an industry often defined by rapid innovation and high-stakes science, long-term success in biotech requires more than breakthrough discoveries—it demands strategic clarity, resilient l...

22 Jul 34min

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Jun 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Mai 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Apr 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Mar 14min

Populært innen Vitenskap

fastlegen
romkapsel
liberal-halvtime
jss
tingenes-tilstand
forskningno
tomprat-med-gunnar-tjomlid
rekommandert
sinnsyn
villmarksliv
rss-paradigmepodden
fjellsportpodden
rss-nysgjerrige-norge
rss-kunstig-intelligens-med-elisabeth-maren-og-morten
rss-rekommandert
tidlose-historier
nordnorsk-historie
rss-inn-til-kjernen-med-sunniva-rose
psykopoden
grunnstoffene